Shining the omics microscope on the mechanism of action of compounds used in HIV cure strategies

Vorinostat is currently being evaluated in clinical trials in a shock and kill approach to cure HIV. Transcriptomic and proteomic profiling of Vorinostat in primary CD4 T cells has identified noteworthy off-target effects, subject-to-subject variation, as well as biomarkers that may be monitored to confirm compound exposure.